Severe Ulcerative Perniosis Treated With Botulinum Toxin
Botulinum ToxinPerniosis (also known as pernio or chilblains), is a condition characterized by the development of pruritic, painful erythrocyanotic skin lesions induced by exposure to cold temperatures.² When perniosis occurs in conjunction with clinical or laboratory features of systemic lupus erythematosus, the condition is further classified as chilblain lupus erythematosus (CHLE). CHLE is a rare condition w …
Botulinum Toxin
Acitretin for Psoriasis | Therapeutic Cheat Sheet
acitretinPustular psoriasis can present quickly and pose a life-threatening emergency. Acitretin is the only systemic retinoid FDA-approved for treatment of psoriasis, specifically both pustular and severe plaque-type psoriasis.1Systemic retinoids such as acitretin are utilized heavily in dermatology, and practitioners must be knowledgeable about all of the FDA-approved and off-label applications as well a …
acitretin
Thalidomide for Dermatologic Conditions | Therapeutic Cheat Sheet
ThalidomideThalidomide was introduced in the 1950s as a “safe” sleeping medication; however, it quickly became vilified and was removed from the market for its severe teratogenic effects, most commonly phecomelia, or loss of arms and legs. Despite these devastating birth defects, thalidomide has a variety of indications for dermatologic conditions, with manageable side effects when used appropriately. We …
Thalidomide
JDD Issue Highlights | November 2021 | Special Focus: Lasers, Lights Sources, and Devices
laserWith a special focus on lasers, light sources, and devices, the November issue of the Journal of Drugs in Dermatology features an outstanding line up of editorials and original articles on topics ranging from deoxycholic acid (ATX-101) for fat reduction,  treating molluscum contagiosum, skincare for neonates and infants, laser in the treatment of granulomas on the nose, and everything in between …
laser
Oral Glycopyrrolate for Hyperhidrosis | Therapeutic Cheat Sheet
Glycopyrrolate for hyperhidrosisHyperhidrosis affects up to 4.8% of people in the United States, causing significant impacts in patient quality of life.1 Often times, the etiology of symptoms cannot be identified, resulting in a subset of disease termed “primary hyperhidrosis.” Symptoms may be focal or generalized. Because there is a scarcity of FDA-approved treatments for primary hyperhidrosis, treatment often requires a mu …
Glycopyrrolate for hyperhidrosis
error

Enjoy this blog? Please spread the word :)